Thermo Fisher Science估计收入并提升2025年的指引, 提升股票前景。 Thermo Fisher Scientific beat earnings estimates and raised 2025 guidance, boosting stock outlook.

Thermo Fisher Science报告说,第二季度收入强劲,5.36美元和108.6亿美元的收入超过预期。 Thermo Fisher Scientific reported strong second-quarter earnings, with $5.36 EPS and $10.86 billion in revenue, surpassing expectations. 该公司将2025年全年收入指导提高到22.22-22.84美元/股,Q3预测为5.46-5.51美元。 The company raised its 2025 full-year earnings guidance to $22.22–$22.84 per share and its Q3 forecast to $5.46–$5.51. 机构投资者拥有公司89.23%的股份,而包括协同资产管理和两点资本管理在内的几家公司则增加了股份。 Institutional investors own 89.23% of the company, while several firms, including Synergy Asset Management and Two Point Capital Management, increased their stakes. 过去90天内幕销售总额超过30 000股,但内幕销售仍占公司股份的0.33%。 Insider sales totaled over 30,000 shares in the past 90 days, though insiders still hold 0.33% of the company. 股价为525.07美元,市场上限为198.27亿美元,市场上限为198.27亿美元。 股价的“Moderate Buy”评级一致,目标价格为585.37美元。 The stock, trading at $525.07 with a market cap of $198.27 billion, has a consensus “Moderate Buy” rating and a target price of $585.37.